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Page 19several facets of everyday practice. However, to our knowledge, no literature regarding
the application of the underpinning principles, general safety, and potential of this
versatile class to the perioperative patient has been published. This study provides an
overview of polymer therapeutics applied to clinical surgery, including the evolution of
this demand-oriented scientific field, cutting-edge concepts, its implications, and limita-
tions, illustrated by products already in clinical use and promising ones in development.
surgical practice. Exposure of the practising surgeon to this versatile class is crucial to
evaluate and maximise the benefits that this established field presents and to attract a
new generation of clinician–scientists with the necessary knowledge mix to drive highly
successful innovation.Background
Polymer therapeutics represents a highly successful
nanomedicine class that has enjoyed extensive success
from aesthetic surgery to neoadjuvant oncology,
features in the top 10 US pharmaceutical sales lists, is
arguably the most successful first-generation
nanomedicine class, and is well established in perioper-
ative use (Duncan, 2014). Polymer therapeutics offerl of Interdisciplinary Nanomed
article under the terms of thsubstantially different properties to conventional coun-
terparts including passive accumulation at target sites
and bioresponsive activation and lend themselves
extensively to custom-engineered solutions for specific
clinical demands. A working knowledge of this
burgeoning scientific field is imperative, for the sur-
geon to evaluate the significantly different properties
compared with conventional therapy, safeguardicine published by John Wiley & Sons Ltd and the British Society for Nanomedicine
e Creative Commons Attribution License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited.
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development process (Duncan and Gaspar, 2011; Gaspar
and Duncan, 2009).
This study provides an overview of polymer
therapeutics applied to clinical surgery in its several
subspecialties, including the evolution of this demand-
oriented scientific field, cutting-edge concepts, its
implications, and drawbacks, illustrated by an exten-
sive review of products already in clinical use and
promising ones in advanced stages of development.Method
A comprehensive database search of MEDLINE, EMBASE,
and Pubmed Central was performed. The search was
limited to studies in English, using the Boolean search
string “polymer and therapeutic” and “surgery” (all
subspecialties). Seminal works underpinning the princi-
pal tenets of polymer therapeutics were included. Title
and abstract of the primary literature were reviewed
for relevance and included in the review. This literature
was back and forward referenced using the Web of
Knowledge™ database.Literature Review
History and working definitions
Evolution towards the microscale has represented a
paradigm shift in surgical practice since Carrel’s studies
on vessel anastomosis (Carrel, 1902). Jacobson and
Suarez introduced the benefits of the operating micro-
scope in the 1960s, followed by the first successful freeFigure 1. The five main subdisciplines of nanomedicine (European forw
mer therapeutics to these subdisciplines).
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(Kriss and Kriss, 1998; Tamai, Komatsu, Sakamoto,
et al., 1970). The adoption of these techniques across
surgical specialties within coronary vessel repair,
otolaryngology, and head and neck surgery bears
witness to their success. The continuous surgical drive
towards the infinitesimal and its attendant benefits
necessarily demanded an exploration of the next fron-
tier represented by the nanometre scale.
Nanomedicine uses nanosized (between 1 and
100 nm) tools addressed toward the diagnosis, preven-
tion, and treatment of disease – molecules that are of
much larger size than conventional drugs (European Sci-
ence Foundation, 2005). Modern awareness of the bene-
fits of nanomedicine dates back to Paul Ehrlich’s first
low-molecular-weight synthetic chemical entities
(Duncan, 2014). Since then, nanomedicine has
expanded into five overlapping subdisciplines (Fig. 1).
Polymer therapeutics are nanoscale therapeutics
and drug delivery systems, pioneered by Herman
Staudinger’s ground-breaking work on covalently linked
macromolecules, popularised and expanded through
the work of Kopeck, Ringsdorf, and Duncan (Duncan
and Gaspar, 2011; Duncan and Vicent, 2013). The term
“polymer therapeutics” has evolved to an umbrella
term encompassing a number of heterogeneous entities
including polymeric drugs, polymer–drug conjugates,
and polymer–protein conjugates (Fig. 2) (Duncan,
2003). Polymer therapeutics lends itself particularly
well to the concept of demand-to-supply research and
therefore presents an important opportunity for theard look consensus conference, 2004, and the relationship of poly-
Figure 2. Diagrammatic representation of different types of polymer therapeutics. The presence of a water-soluble polymer is the com-
mon denominator. Examples are given in parentheses. (a) Polymeric drug; (b) polymeric drug modified by the addition of pendant groups;
(c) polymer–protein conjugate; (d) polymer–drug conjugate; and (e) PEGylated micelles.
Polymer Therapeutics in SurgeryE. A. Azzopardi et al.surgeon–scientist to translate a clinical demand to a
custom-engineered product. This demands a working
knowledge of the major differences and designs
distinguishing a polymer therapeutic from a conven-
tional alternative.
Design: custom engineering from bench to
bedside and back
The common denominator for all polymer therapeutics
is the possession of a water-soluble polymer. Polymers
consist of repeating component units (monomers) to
produce a macromolecular structure with unique phys-
icochemical characteristics. Several types of polymers
are employed, and a simple working classification is
provided in Table 1. Polymeric drugs represent the
simplest form of polymer therapeutic (Fig. 2a). Here,
the polymer itself is the active drug. Applications
include structural tissue support, increasing lubrica-
tion, structural volume expansion such as hyaluronic
acid (HA), and plasma volume expansion such as
dextran.
The polymer may be customised to a clinical niche by
the induction of pendant branches along the main back-
bone chain. In the natural form, injectable HA is locally
degraded within 48 h (Fakhari and Berkland, 2013).
However, HA cross-linking increases resistance to
biodegradability by endogenous human hyaluronidase
enzyme (further applications of HA are considered inMacromolecular Status and the Enhanced Permeability
Retention Effect section). Conjugation to 1,4-
butanediol diglycidal ether and divinyl sulphone results
in very predictable degradation over time. 1,4-
Butanediol diglycidal ether and divinyl sulphone are
currently the only two cross-linking agents licenced
for dermal injectable use (Bray, Hopkins, and Roberts,
2010; Fullana and Wnek, 2013). Dextrin is another
example of a Food and Drug Administration (FDA)-ap-
proved, largely linear polymer, which is rapidly
digested by naturally occurring amylase at physiologi-
cal concentrations. However, it can be modified by
increasing amounts of succinoylation (Fig. 2b). In the
presence of physiological amylase activity, this provides
a highly predictable and custom-engineered degrada-
tion rates and differentially, in microenvironments
within the body, where amylase might accumulate
(Azzopardi, Camilleri, Moseley, et al., 2013a).
“Pendant groups” can additionally serve as “linkers”
enabling chemical bonding of a polymer to a bioactive
molecule of interest, a process termed conjugation.
For example, HA has been conjugated to various mole-
cules of interest including antiinterleukin-1β and
antitumour necrosis growth factor-α monoclonal anti-
bodies (Duncan and Vicent, 2013). Polymer–drug conju-
gates are arguably the commonest forms of polymer
therapeutics and, like other polymer therapeutic
subclasses, have properties substantially distinct from2016 | Volume 1 | Issue 1 |
Page 21
Table 1. Classification of polymers and prominent examples in clinical use.
Classification Subclasses Polymer example Clinical example Surgical specialty
Biodegradability Nonbiodegradable PEG PEG recombinant Gastrointestinal
IFN α2b (hepatitis C) Hepatobiliary
PEG-IFNα-2b Melanoma surgery
Biodegradable HA Dermal fillers
(aesthetic surgery)
Aesthetic (Bray et al., 2010;








PEG-Erythropoietin Anaemia (Duncan and
Vicent, 2013)
PEG-anti-TNF Fab Rheumatoid arthritis





Polyvinylpyrrolidone Povidone iodide Antiseptic (Ascher, Bayerl,






Linear Dextrin Dextrin Nephrology












PEG, poly(ethyl glycol); HA, hyaluronic acid; IFN α2a, interferon alpha 2a; IFN α2b, interferon alpha 2b.
*Glutamic acid, lysine, alanine, and tyrosine.
Polymer Therapeutics in Surgery E. A. Azzopardi et al.the conventional alternatives (Table 2). Additionally,
conjugation creates new, original macromolecules,
affording intellectual property space, which is crucial
for successful commercialisation (Pinter, Horvath,
Bujdoso, et al., 2009).Table 2. Examples of properties conferred by conjugation in polymer
Polymer therapeutic
Improved biological efficacy (Duncan, 2003)
Extended plasma circulation time (Koburger, Hübner, Braun
2010)
Shielding from immunogenicity and premature biofouling a
clearance (Werle and Bernkop-Schnürch, 2006)
Enhanced permeability and retention effect (macromolecu
(Maeda, 2010; Maeda, Bharate, and Daruwalla, 2009)
Potential for “masking/unmasking” and locally triggered
reinstatement of bioactivity (biodegradable polymers)
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permeability retention effect
Conjugating a conventional “small molecule” to a poly-
mer of adequate size creates a macromolecule. As
molecular size increases, filtration at the glomerulustherapeutics.
Conventional alternative
Conventional biologic efficacy
, et al., Conventional plasma residence times,
clearance, and degradation
nd Conventional risk of immunological
reaction, sequestration, and clearance
le) Indiscriminate distribution (conventional
small molecule)
N/A
Polymer Therapeutics in SurgeryE. A. Azzopardi et al.decreases, a happy state of affairs if the newly synthe-
sised molecule is to avoid perioperative nephrotoxicity
whilst simultaneously increasing plasma residence time
(Azzopardi, Ferguson, and Thomas, 2014a). Colistin, for
example, is increasingly used to treat multidrug-
resistant surgical infection. Its use is limited by its rep-
utation for nephrotoxicity (Azzopardi, Boyce, Thomas,
et al., 2013b). However, conjugation to dextrin, using
succinoyl linking groups, resulted in substantial reduc-
tion of kidney clearance and absence of any observed
clinical toxicity in vivo within Sprague Dawley rats
(Azzopardi et al., 2014a).
Conversion of a conventional “small molecule” anti-
biotic into a macromolecule may benefit from passive,
size-based targeting to an inflamed area (Azzopardi,
Ferguson, and Thomas, 2013c). The enhanced perme-
ability and retention (EPR) effect refers to the ability
of macromolecules to passively accumulate at the site
of enhanced vascular permeability and be selectively
retained therein (Maeda, 2012). This principle has been
extensively applied to the design of clinically successful
antineoplastic and neoadjuvant drugs, inflammatory
diseases such as rheumatoid arthritis, and other chronic
conditions (Duncan, 2011; Duncan and Gaspar, 2011;
Duncan and Vicent, 2013; Hardwicke, Hart, Bell,
et al., 2011). This concept has been extensively
exploited in the design of next generation of chemo-
therapeutic agents entering clinical practice, such as
polyethyleneglycol (PEG)-asparaginase (OncasparR,
PEG-L-asparaginase, Sigma-Tau Pharmaceuticals, Inc.,
Gaithersburg, MD, USA) (Duncan, 2011).
It is worth noting that whilst EPR has been demon-
strated to be highly successful in preclinical species, it
has been less successful clinically. This could be
accounted for by several possibilities including failure
of the construct to address a specific niche, including
real-life drug interactions that might diminish the effi-
cacy of EPR and does highlight the need for closer clini-
cian collaboration in husbanding the strategy for
construction of a particular polymer therapeutic to
address a particular clinical niche. Meanwhile,
targeting that is augmented by either specific ligandsFigure 3. The polymer mask–unmask protein therapy principle. During
same time shielding the body from potential toxicity. At the target site
to release back the bioactive molecule, with its activity reinstated.or radiotherapy may be more prerequisite for treat-
ment of diseases that are otherwise not terminal.Bioresponsive polymer therapeutics and smart
release
Classically, nonbiodegradable synthetic polymers,
including PEG, N-(2-hydroxypropyl) methacrylamide
(HPMA), and poly(lactic-co-glycolic) acid, comprise
the majority of clinical success stories (Pasut and Vero-
nese, 2009; Duncan, 2009). PEG conjugates are clini-
cally well tolerated and extensively used. The surgical
community is well versed with applications of some of
these polymers in suture materials (Najibi, Banglmeier,
Matta, et al., 2010). More recently, however, the advan-
tages of biodegradable polymers, including the ability to
respond to biological stimuli, have been intensively
studied.
The degradation of bioresponsive polymers can be
custom engineered to suit particular clinical demands
(Design: Custom Engineering from Bench to Bedside
and Back section), based on either exogenous enzymes
co-administered to the patient (in their native form, or
even themselves as polymer–enzyme conjugates)
(Duncan, Gac-Breton, Keane, et al., 2001). More
recently, an elegant approach for “shielding” the bioac-
tive payload in transit, followed by localised enzymatic
controlled release and restitution of bioactivity, has
been described (Duncan, Gilbert, Carbajo, et al.,
2008). This depends on conjugation to biodegradable
polymers. The polymer masking–unmasking protein
therapy principle involves a multifunctional biodegrad-
able polymer to envelope the payload of interest whilst
allowing locally triggered polymer degradation and
reinstatement of the masked bioactive’s activity (Fig. 3)
(Duncan et al., 2008). The masked conjugate offers im-
proved biological efficacy, extended plasma circulation
time, and reduced proteolytic degradation and protein
immunogenicity (Roberts, Bentley, and Harris, 2002;
Werle and Bernkop-Schnürch, 2006). Locally triggered
unmasking at the intended site allows controlled
reinstatement of bioactivity. Triggered release can betransit, the polymer “masks” the bioactive from the body, at the
, the bioresponsive polymer is degraded (using various approaches)
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Polymer Therapeutics in Surgery E. A. Azzopardi et al.effectively controlled and predicted by the length of
the polymer and the amount of linker modification
(Azzopardi, 2013b).
Physicochemical customisation
Conjugation can also radically alter mechanical, tensile,
and viscoelastic properties. The effect of HA conjugation
on its stability and potential as controlled release mech-
anism has already been referred to in Design: Custom
Engineering from Bench to Bedside and Back section.
Additionally, HA enjoys a central role in reconstructive
surgery and regenerative medicine. It is present in most
body fluids and tissues, including dermis, vitreous
humour, and hyaline cartilage (Azzopardi, Ferguson,
and Thomas, 2013d; Fakhari and Berkland, 2013; Griffith,
2000; Zheng Shu, Liu, Palumbo, et al., 2004). Its avidity
to water molecules provides viscoelastic properties, but
HA also simultaneously acts as mechanical support, bio-
logical scaffold, making it a prime target for cosmetic
and facial rejuvenation applications (Garg and Hales,
2004). At a cellular level, its roles are multiple and com-
plex. It is binding other matrix molecules, guiding cell
proliferation and differentiation, and guides morphogen-
esis, wound repair, and inflammation (Zheng Shu et al.,
2004). Recent studies on naked mole rats report that
HA plays an important role in mediating its remarkable
resistance to cancer (Tian, Azpurua, Hine, et al., 2013).
It is therefore discussed as an elegant example of the
versatile potential for polymer therapeutics to custom-
engineered solutions to complex clinical problems.
Photocross-linked HA affords mechanical stability
and has found favour in cartilage tissue engineering,
cardiac repair, molecule delivery, valvular engineering,Table 3. Examples of promising polymer therapeutics in development
Polymer Polymer therapeutic Examp




















Poloxamer Various In vivo
HA, hyaluronic acid; HPMA, N-(2-hydroxypropyl) methacrylamide.
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Page 24control of stem cell behaviour, andmicrodevices (Burdick
and Prestwich, 2011). Chondrocytes within these modi-
fied HA hydrogels also resulted in cartilage production
within the porous network (Allison and Grande-Allen,
2006). Use of HA for nonsurgical facial rejuvenation is
well established (Greco, Antunes, and Yellin, 2012).
In the Pipeline
There are a number of promising polymer therapeutics
in advanced stages of experimentation in vivo relevant
to the practising surgeon, and salient examples are
summarised in Table 3. Examples serve to expose the
reader to the opportunities presented by this field in
several aspects for future surgical practice.
Pharmacosurgery: the potential of modality
combination treatment
Polymer therapeutics offers the exciting ability to
custom-designed molecules for specific perioperative
demands. Such pharmacosurgical therapy may have
the potential to increase the scope and magnitude of
therapy beyond the conventional. The following section
lists some common examples of polymer therapeutics in
surgical practice as well, high-profile candidates for
clinical entry, and specific areas of development includ-
ing management of surgical site infection, oncological
surgery, and radiotherapy.
Localised lymphatic distortion frequently accom-
panies surgically treated conditions in oncological
surgery, such as lymphatic dissection. It is rational to
entertain the notion that this significant lymphatic
distortion may serve to amplify and prolong an EPR
effect, making it possible to specifically engineer.
les and development
cation of sentinel lymph nodes in breast cancer and
ma (phase III)
ant melanoma in phase 2 clinical trial (Maeda, Fang,
a, et al., 2003)
preclinical phase (Azzopardi et al., 2011a)
preclinical phase (Duncan and Vicent, 2010; Hardwicke
2010, 2011; Serbest et al., 2005)
breast cancer (Hardwicke, Ferguson, Moseley, et al.,
preclinical phase (Medina et al., 2011; Sikkink et al., 2009)
Polymer Therapeutics in SurgeryE. A. Azzopardi et al.bioactive entities to selectively target the affected
region. Moreover, the EPR (Maeda, 2012) effect is
enhanced by radiotherapy, and targeting of polymer–
drug conjugates by radiotherapy has been clinically
observed (Ke, Milas, Charnsangavej, et al., 2001).
These examples postulate the emergence of
“Pharmacosurgery” as the synergistic perioperative
combination of surgery and bioactive pharmacological
agents, more efficacious in simultaneous administra-
tion than the individual therapeutic modality, as an
avenue of significant interest in perioperative diagnosis
and treatment.
Targeted antibiotic delivery to surgical site
infections
Several macromolecular entities have been reported to
accumulate at the infected site, despite the absence of
specific receptors or transport mechanisms (Evans,
Evans, and Gorbach, 1973; Laverman, Boerman, Oyen,
et al., 1999, 2001a; Laverman, Dams, Storm, et al.,
2001b; Melendez-Alafort, Nadali, Pasut, et al., 2009).
Several studies report that the notion of rapid, passive,
size-based accumulation around foci of acute infection
is feasible (Azzopardi 2013a). It presents the ability to
target a dose of antibiotic selectively and rapidly to-
wards surgical site infection. Such examples include
PEG-ubiquicidin, 99Tc-labelled poly(ethylene glycol)-
coated liposomes (99mTc-PEG-liposomes), and gallium-
transferrin (Dams, Reijnen, Oyen, et al., 1999;
Laverman et al., 1999, 2001b; Oyen, Boerman, Storm,
et al., 1996). 99Tc-labelled proteins including aprotinin
(6512 g/mol) allow rapid localisation around infected
foci induced in vivo animal models (2 h), and their con-
centration was up to 6.5 times higher than control tis-
sue (Komarek, Kleisner, Komarkova, et al., 2005). A
correlation between intraabdominal abscesses and the
magnitude of effect of EPR has also been reported with
some compounds (Sikkink, Reijnen, Laverman, et al.,
2009). Polymer therapeutics therefore presents the
potential for a clinically feasible avenue to the man-
agement of multidrug-resistant surgical site infection.
Polymer therapeutics in tissue regeneration
Poloxamers are nonionic triblock copolymers composed
of a central hydrophobic chain of polyoxypropylene
(poly(propylene oxide)) flanked by two hydrophilic
chains of polyoxyethylene (poly(ethylene oxide)). It
has been recently shown that improvement in apoptosis
and cell viability mediated by poloxamer 188 may lead
to increased fat graft viability (Medina, Nguyen,Kirkham, et al., 2011) and recovery of neuronal tissue
from mechanical injury (Serbest, Horwitz, and Barbee,
2005).
Recently, succinoylated dextrin conjugated to
recombinant EGF has shown promise as a controlled
release approach with excellent results on in vivo ani-
mal models of chronic wounds (Hardwicke, Moseley,
Stephens, et al., 2010; Hardwicke, Schmaljohann,
Boyce, et al., 2008a; Hardwicke et al., 2011). This
product combines the aim of protecting the growth fac-
tor from the harsh chronic wound fluid environment but
allows reinstatement of its activity when exposed to
α-amylase using the polymer masking–unmasking pro-
tein therapy concept.
Polymer therapeutics in oncological surgery
Despite its widespread acceptance, literature reports
that injection of blue dye at the site of primary tumour
for the identification of dye sentinel lymph node biopsy
remains largely nonstandardised (Sondak, King, Zager,
et al., 2013). Isosulfan blue or Patent Blue V dye
followed by methylene blue dye has been used for sen-
tinel lymph node mapping, despite controversy about
their comparability and safety (Liu, Truini, and Ariyan,
2008; Neves, Reynolds, Hazard, et al., 2011). The com-
bined use of radiolabelled colloid is also widespread,
and recently, the FDA approved 99Technetium–sulphur
colloid for sentinel lymph node identification in breast
cancer (Pharmalucence press release, n.d.). However,
this approval was based on retrospective data showing
the noninferiority of the latter to the blue dye method.
Tilmanocept is a recently described mannosylated
dextran-based polymer therapeutic for sentinel lymph
node imaging, which may offer an innovative solution
for melanoma and breast cancer patients and requires
no manipulation before injection. It is reported to bind
tightly to CD 206 mannose receptors on the surface of
reticuloendothelial cells resident in lymph nodes for
up to 30 h (Sondak et al., 2013).
More recently, superparamagnetic iron oxide con-
trast agent injected subcutaneously into the breast
rather than intravenously has gained FDA approval for
the purpose of sentinel lymph node identification and
has demonstrated an identification rate in humans that
is noninferior to the standard technique (Duncan and
Gaspar, 2011).
The EPR effect has been widely adopted to target
biologically active payloads to solid tumours. In 2011,
PEG-interferon α-2b has recently been approved as an
adjuvant therapy for the treatment of high-risk2016 | Volume 1 | Issue 1 |
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able stage III melanoma reported a significantly in-
creased median recurrence-free survival. However,
overall survival was not significantly different to con-
trols (Ditrolio, Simeone, DI Lorenzo, et al., 2012).
HPMA–copolymer–DACH platinate has recently entered
phase II trials for melanoma. Similarly, first clinical
studies with transferrin-targeted polymer–cyclodextrin
nanoparticle small interfering ribonucleic acid delivery
systems have demonstrated nanoparticle localisation to
melanoma tissue (Davis, 2009; Galanski and Keppler,
2012).
Safety of Polymer Therapeutics
The clinical success of several polymers as plasma ex-
panders, and egregious fall from grace of others, serves
to illustrate the imperative for clinical knowledge of
this field in the interest of patient safety. This section
summarises current controversies and cautions towards
polymer therapeutics in surgical practice (Table 4).
Hydroxyethyl starch was used until recently to
expand the volume of circulating plasma but carried
an increased risk of renal dysfunction and mortality
over a 90-day follow-up in patients who received
hydroxyethyl starch compared with crystalloids.
Increased mortality in patients with sepsis was also
observed prompting their UK-wide recall (Brunkhorst,
Engel, Bloos, et al., 2008; MHRA, 2013; Myburgh, Finfer,
Bellomo, et al., 2012; Perner, Haase, Guttormsen,
et al., 2012; Zarychanski, Abou-Setta, Turgeon, et al.,
2013). Clinical success of dextran has been mixed. Its
use as volume expander has been limited by a reported
aptitude for causing renal impairment (Bhatt, Neppalli,
Kelley, et al., 2011). Its anticoagulant properties have,




Theoretical risk of toxic accumulati
Dextrans May generate an immunoglobulin-M
Degraded slowly (Azzopardi et al., 2
Tend to form nondegradable produc
1973)
HES HES fractions may cause hypersensit
haemorrhage (Vercauteren, Bruneel
Metabolites As with all drugs, it should be ensur
toxicological reaction (Duncan and V
HES, hydroxyethyl starch.
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contended (Djohan, Gage, and Bernard, 2010; Riva,
Chen, Tan, et al., 2012) rather than the limited quanti-
ties associated with administration of medicinals
(Azzopardi, McWilliams, Iyer, et al., 2009; Boussekey,
Darmon, Langlois, et al., 2010; Gattas, Dan, Myburgh,
et al., 2012). It is likely that these effects are clinically
relevant with the significant amounts used as volume
expanders rather than the limited quantities that
would be used in their role as polymers for drug conju-
gation. However, these cautionary tales underscore the
importance of the surgeon’s familiarity with potential
polymer therapeutic side, as the ultimate custodian of
patients’ safety.
Finally, renal failure is a frequent perioperative com-
plication (Mitchell, 2013). An advantage of macromo-
lecular constructs is increased plasma residence time
by way of avoiding filtration at the kidney, thereby
decreasing unwanted nephrotoxicity. The use of biode-
gradable polymers like dextrin and HA present the
potential for degradation and metabolism into normally
produced metabolites such as glucose, maltose, and
isomaltose (dextrin, dextran, and starch) or amino
acids (HA). However, nonbiodegradable polymers such
as PEG do present the theoretical risk of toxic accumu-
lation lysosomal storage-like diseases, and other meta-
bolic aberrations become theoretically possible,
especially when chronic administration would be antic-
ipated (Gaspar and Duncan, 2009).
The US Nanotechnology Characterisation
Laboratory’s work is of interest to this section in having
defined an assay cascade with which to assess, in a
timely and rationalised manner, the physical attributes,
in vitro biological properties, and in vivo compatibility
(in animal models) of submitted requests, througholymer therapeutic
on in lysosomal storage-like disorders
response (Azzopardi, Ferguson, and Thomas, 2011b)
011b; Battisto and Pappas, 1973)
ts during chemical modification (Battisto and Pappas,
ivity and interfere with coagulation processes causing
, Schacht, et al., 1990; Zarychanski et al., 2013)
ed that the metabolites are assessed for any adverse/
icent, 2013; Gaspar and Duncan, 2009)
Polymer Therapeutics in SurgeryE. A. Azzopardi et al.which it standardises the preclinical characterisation of
nanomaterials intended for cancer therapeutics and
diagnostics (Gaspar and Duncan, 2009). To the same
end, a sister European institution, the European coun-
terpart facility, EU-Nanotechnology Characterisation
Laboratory, has been recently launched (Carrel, 1902).
Discussion
Polymer therapeutics has evolved into a clinically
successful branch of nanomedicine. The extensive ver-
satility of the building blocks themselves (polymer,
linker, and drug) and the custom-engineering strategies
available open up exciting innovative and sustainable
horizons to pressing surgical problems such as surgical
site infection, tissue regeneration, reconstruction,
and oncology.
However, transferring the benefits to the bedside
requires dual expertise in surgery and polymer thera-
peutics. Central to the success of polymer therapeu-
tics, therefore, is that the demand-to-supply ethos of
the field is nourished by the dual training of surgeon–
scientists. Clinical academics are ideally placed
between demand and supply ends of the research trans-
lational chain, and it is essential that a new generation
of clinician scientists is attracted to the field if the suc-
cess stories of polymer therapeutics in other clinical
areas are to be replicated across the surgical special-
ties. The surgical community does not afford to be left
out from being intimately involved in the development
of this technology and underlying paradigms, and this is
being pioneered by clinical–academic programmes in
the UK to some extent, and nascent training
programmes geared toward the dual clinical–academic
development have yielded interesting results
(Azzopardi, Ferguson, and Thomas, 2011a, 2013e,
2014b; Azzopardi et al., 2013c,b; Madani, Naderi,
Dissanayake, et al., 2011). More importantly, exposure
to this ongoing revolution may help maintain and
develop a clinically oriented, demand-driven ethos in
this specialism. It is essential to attract a new genera-
tion of clinician–scientists with the necessary knowl-
edge mix to drive highly successful translational
innovation whilst preserving the surgeon’s role as the
ultimate guardian of patient safety.
This study has provided an overview of polymer
therapeutics applied to clinical surgery, including the
evolution of this demand-oriented scientific field,
cutting-edge concepts, its implications, and draw-
backs, illustrated by an overview of products already
in clinical use and promising ones in advanced stagesof development. This journal encourages and welcomes
manuscripts situated at the interface between the
disciplines of clinical surgery regenerative medicine,
cell biology, and pharmaceutical sciences. It is time
for the surgical community to step up to the plate.Acknowledgments
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